| | Variables | |
| | Female, (%) | 122 (46.7) | | Age (years), mean (SD) | 56.13 (15.8) | | BMI (), mean (SD) | 27.1 (6.1) | | Lifestyle | | | Smokers (), (%) | 50 (19.2) | | Current alcohol (), (%) | 129 (49.4) | | Overuse alcohol, (%) | 42 (16.1) | | Etiology of liver disease | | | Hepatitis B, (%) | 79 (30.3) | | Liver cirrhosis, (%) | 64 (24.5) | | Alcoholic liver disease, (%) | 63 (24.1) | | Nonalcoholic fatty liver disease, (%) | 52 (19.9) | | Hemochromatosis, (%) | 23 (8.8) | | Alcoholic liver insufficiency, (%) | 19 (7.3) | | Chronic liver insufficiency, (%) | 17 (6.5) | | Hepatitis C, (%) | 15 (5.7) | | Autoimmune hepatitis, (%) | 9 (3.4) | | Hepatocellular carcinoma, (%) | 9 (3.4) | | Primary biliary cholangitis, (%) | 8 (3.1) | | Alfa-1-antitrypsin deficiency, (%) | 6 (2.3) | | Wilsons, (%) | 1 (0.4) | | Primary sclerosing cholangitis, (%) | 1 (0.4) | | Budd-Chiari, (%) | 1 (0.4) | | Comorbidities | | | Obesity, (%) | 72 (27.6) | | Hypertension, (%) | 63 (24.1) | | Type 2 diabetes, (%) | 53 (20.3) | | Cardiac disease, (%) | 38 (14.6) | | Autoimmune diseases, (%) | 37 (14.2) | | Chronic pulmonary disease, (%) | 32 (12.3) | | History of stroke or hemiplegia, (%) | 15 (5.7) | | Asthma, (%) | 11 (4.2) | | Localized solid tumor, (%) | 11 (4.2) | | Chronic kidney disease, (%) | 9 (3.4) | | Dementia, (%) | 6 (2.3) | | No comorbidities, (%) | 99 (37.9) | | Charlson Comorbidity Index, mean (SD) | 3.26 (2.5) | | Number of hospital admissions in the last 12 months prior to COVID-19 diagnosis, mean (SD) | 1.0 (2.6) | | Hospitalization length (cumulated), median (IQR) | 13 (3-33.50) | | Biochemistry in plasma | | | Hemoglobin, mean (SD) | 8.2 (1.3) | | Platelet (×109/L), mean (SD) | 219 (97.7) | | ALAT (U/L), mean (SD) | 40.9 (35.1) | | Albumin (g/dL), mean (SD) | 34.8 (8.1) | | Bilirubin (μmol/L), mean (SD) | 17 (29.4) | | INR, mean (SD) | 1.1 (0.3) | | Creatinine (μmol/L), mean (SD) | 89.8 (110.7) | | Sodium (mmol/L), mean (SD) | 137.3 (11) | | C-reactive protein (mg/dL), mean (SD) | 11.2 (24.6) | | Treatment () | | | Specific medication therapy of CLD | | | Vitamin B, (%) | 44 (16.9) | | Furosemide, (%) | 32 (12.3) | | Spironolactone, (%) | 29 (11.0) | | Venesection, (%) | 16 (6.1) | | Antiviral nucleos(t)ide analogues, (%) | 14 (5.4) | | Propranolol, (%) | 10 (3.8) | | Nutrients (calcium, vitamin D, zinc, magnesium, etc.), (%) | 7 (2.7) | | Ursodeoxycholic acid, (%) | 7 (2.7) | | Rifaximin, (%) | 6 (2.3) | | Albumin infusion, (%) | 5 (1.9) | | Ciprofloxacin (SBP prophylaxis), (%) | 4 (1.5) | | Anticoagulation therapy, (%) | 3 (1.1) | | Prednisolone, (%) | 3 (1.1) | | Immune modulation, (%) | 2 (0.8) |
|
|
